Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short-term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis.
Puro V, De Carli G, Orchi N, Palvarini L, Chiodera A, Fantoni M, Del Borgo C, Iemoli E, Niero F, Monti M, Micheloni G, Caggese L, Lodesani C, Raineri G, Massari M, Drenaggi D, Ippolito G; Italian Registry of Antiretroviral Post-Exposure Prophylaxis. Puro V, et al. Among authors: chiodera a. J Biol Regul Homeost Agents. 2001 Jul-Sep;15(3):238-42. J Biol Regul Homeost Agents. 2001. PMID: 11693431
Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A; ICoNA Foundation Study Group. Cicconi P, et al. HIV Med. 2010 Feb;11(2):104-13. doi: 10.1111/j.1468-1293.2009.00750.x. Epub 2009 Sep 1. HIV Med. 2010. PMID: 19732176 Free article.
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group. Prosperi MC, et al. J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927. J Med Virol. 2010. PMID: 20981785
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.
Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A; SEHERE consortium. Prosperi MC, et al. J Antimicrob Chemother. 2011 Aug;66(8):1886-96. doi: 10.1093/jac/dkr171. Epub 2011 May 30. J Antimicrob Chemother. 2011. PMID: 21624929
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.
Prosperi MC, Di Giambenedetto S, Fanti I, Meini G, Bruzzone B, Callegaro A, Penco G, Bagnarelli P, Micheli V, Paolini E, Di Biagio A, Ghisetti V, Di Pietro M, Zazzi M, De Luca A; ARCA cohort. Prosperi MC, et al. BMC Med Inform Decis Mak. 2011 Jun 14;11:40. doi: 10.1186/1472-6947-11-40. BMC Med Inform Decis Mak. 2011. PMID: 21672248 Free PMC article.
86 results